The Food and Drug Administration has approved Glenmark's generic Micardis, which had a market value of roughly $40.6 million for the 12-month period ended January 2019.
As generic drugs are placed on higher, non-generic tiers, patient cost sharing for these medications can increase, according to a recent study from Avalere.